Legal & General Group Plc Has $109,000 Stock Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Legal & General Group Plc boosted its holdings in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 65.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 19,245 shares of the company’s stock after acquiring an additional 7,597 shares during the quarter. Legal & General Group Plc’s holdings in Voyager Therapeutics were worth $109,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Barclays PLC grew its stake in shares of Voyager Therapeutics by 55.8% in the 3rd quarter. Barclays PLC now owns 104,462 shares of the company’s stock valued at $612,000 after buying an additional 37,398 shares in the last quarter. Geode Capital Management LLC grew its position in Voyager Therapeutics by 0.6% in the third quarter. Geode Capital Management LLC now owns 1,079,509 shares of the company’s stock worth $6,316,000 after acquiring an additional 6,740 shares in the last quarter. SG Americas Securities LLC increased its stake in shares of Voyager Therapeutics by 86.7% during the 4th quarter. SG Americas Securities LLC now owns 23,044 shares of the company’s stock worth $131,000 after purchasing an additional 10,704 shares during the last quarter. Empowered Funds LLC raised its holdings in shares of Voyager Therapeutics by 5.3% during the 4th quarter. Empowered Funds LLC now owns 47,206 shares of the company’s stock valued at $268,000 after purchasing an additional 2,397 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its stake in shares of Voyager Therapeutics by 23.9% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 39,313 shares of the company’s stock valued at $223,000 after purchasing an additional 7,573 shares during the last quarter. Hedge funds and other institutional investors own 48.03% of the company’s stock.

Insiders Place Their Bets

In other Voyager Therapeutics news, CEO Alfred Sandrock sold 10,885 shares of Voyager Therapeutics stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $3.43, for a total value of $37,335.55. Following the sale, the chief executive officer now owns 430,931 shares of the company’s stock, valued at approximately $1,478,093.33. The trade was a 2.46 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 4.53% of the company’s stock.

Voyager Therapeutics Stock Performance

Shares of NASDAQ:VYGR opened at $3.55 on Friday. Voyager Therapeutics, Inc. has a 52 week low of $2.75 and a 52 week high of $9.55. The firm has a market cap of $196.36 million, a PE ratio of 5.00 and a beta of 1.02. The firm’s fifty day moving average is $3.60 and its 200-day moving average is $5.10.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings data on Tuesday, March 11th. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.24). Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The business had revenue of $4.39 million during the quarter, compared to the consensus estimate of $16.58 million. During the same period last year, the business posted $1.25 earnings per share. Sell-side analysts forecast that Voyager Therapeutics, Inc. will post -0.91 EPS for the current year.

Analyst Ratings Changes

VYGR has been the topic of several research analyst reports. Wedbush restated an “outperform” rating on shares of Voyager Therapeutics in a research note on Wednesday, March 12th. Wells Fargo & Company set a $10.00 price target on shares of Voyager Therapeutics and gave the stock an “overweight” rating in a research note on Wednesday, March 12th. Canaccord Genuity Group lowered their price objective on Voyager Therapeutics from $14.00 to $12.00 and set a “buy” rating on the stock in a research note on Thursday, March 13th. Cantor Fitzgerald restated an “overweight” rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th. Finally, HC Wainwright reiterated a “buy” rating and set a $30.00 price objective on shares of Voyager Therapeutics in a research note on Tuesday, April 8th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $13.97.

Voyager Therapeutics Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.